Common bowel disease treatment may blunt COVID-19 vaccine response: Study

"This is a really important study, showing that a single dose of SARS-CoV2 vaccine is insufficient to generate protective antibody responses in patients treated with anti-TNF drugs," said Nick Powell, co-senior author of the study from Imperial's Department of Metabolism, Digestion and Reproduction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3nxlO6E
via IFTTT